公开(公告)号：US11084798B1

公开(公告)日：2021-08-10

申请号：US17175579

申请日：2021-02-12

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar Alam ,  Leah Cleary ,  Melissa Fleury ,  Zhonghua Pei ,  Richard Steel ,  James Sutton ,  John E. Knox ,  Zachary E. R. Newby

IPC: C07D239/95 ,  C07D401/12 ,  C07D471/04 ,  C07D473/04 ,  C07D403/12 ,  C07D417/04 ,  C07D403/06 ,  C07D401/02 ,  C07D239/80

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

公开(公告)号：US20190270754A1

公开(公告)日：2019-09-05

申请号：US16268444

申请日：2019-02-05

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Muzaffar ALAM ,  Hilary Plake BECK ,  Michael Patrick DILLON ,  Marcos GONZALEZ-LOPEZ ,  James Clifford SUTTON, JR.

IPC: C07D498/04 ,  A61P35/00 ,  C07D487/04 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

公开(公告)号：US20250090533A1

公开(公告)日：2025-03-20

申请号：US18708487

申请日：2022-11-11

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Claire L. Neilan ,  Marcus M. Fischer ,  Kimberline Yang Gerrick ,  Neil E. Bhola

IPC: A61K31/519 ,  A61K31/337 ,  A61P35/00

Abstract: Provided herein is a combination of a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a taxane, and methods of using such combinations to treat diseases or disorders associated with MAT2A, for example, cancer.

公开(公告)号：US12115163B2

公开(公告)日：2024-10-15

申请号：US18405638

申请日：2024-01-05

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Michael Patrick Dillon ,  Claire L. Neilan ,  Marcus Michael Fischer ,  Kimberline Yang Gerrick

IPC: A61K31/519 ,  A61K31/502 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/502 ,  A61P35/00

Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.

公开(公告)号：US20240269143A1

公开(公告)日：2024-08-15

申请号：US18565392

申请日：2022-06-01

Applicant: IDEAYA BIOSCIENCES, INC. ,  GlaxoSmithKline Intellectual Property (No.4) Limited

Inventor： Michael Patrick DILLON ,  Marcus Michael FISCHER ,  Kimberline Yang GERRICK ,  Jenny Laraio ,  Helai Mohammad ,  Kimberly Smitheman

IPC: A61K31/519 ,  A61K31/415 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/415 ,  A61P35/00

Abstract: Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with MAT2A and/or Type I PRMT.

公开(公告)号：US20230303510A1

公开(公告)日：2023-09-28

申请号：US18006991

申请日：2021-07-28

Applicant: Ideaya Biosciences, Inc.

Inventor： Hilary Plake BECK ,  Michael Patrick DILLON ,  Brian Thomas JONES ,  Luisruben Padilla MARTINEZ

IPC: C07D401/04 ,  C07D207/09 ,  C07D413/04 ,  C07D401/14 ,  C07D405/14 ,  C07D403/04

CPC classification number: C07D401/04 ,  C07D207/09 ,  C07D413/04 ,  C07D401/14 ,  C07D405/14 ,  C07D403/04

Abstract: The present invention relates to methods for treating bacterial infections caused by or
Provided and set forth herein are certain cyclized acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I) and Formula II.




Also, provided are pharmaceutical compositions comprising such compounds, and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers, using such compounds and pharmaceutical compositions.

公开(公告)号：US20230257377A1

公开(公告)日：2023-08-17

申请号：US18009182

申请日：2021-06-09

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Richard STEEL ,  Melissa FLEURY ,  Paul A. BARSANTI

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Disclosed herein are certain 2-aminoquinazoline derivatives of Formula (A) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

公开(公告)号：US20220401440A1

公开(公告)日：2022-12-22

申请号：US17756095

申请日：2020-11-18

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Julie Hambleton ,  Jianhong Wang

IPC: A61K31/497 ,  A61K45/06

Abstract: Disclosed herein are dosing regimens for the treatment of cancer mediated by protein kinase C (PKC) with 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide, Compound (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11530220B2

公开(公告)日：2022-12-20

申请号：US16967100

申请日：2019-02-05

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Hilary Plake Beck ,  Marcos Gonzalez-Lopez ,  James Clifford Sutton, Jr.

IPC: A61K31/4985 ,  C07D487/04 ,  A61K45/06

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formula: wherein the letters and symbols a, b, c, d, e, f, A, R1, X1, Ar1 and Ar2 have the meanings provided in the specification.

公开(公告)号：US20210387968A1

公开(公告)日：2021-12-16

申请号：US17426436

申请日：2020-01-30

Applicant: IDEAYA Biosciences, Inc.

Inventor： Hilary Plake BECK ,  Michael DILLON ,  Brian JONES ,  Luisruben P. MARTINEZ

IPC: C07D401/14 ,  C07D401/12 ,  C07D233/64

Abstract: Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.